Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.

TPS8062Background: Current guidelines for SMM recommend active monitoring for progression to symptomatic MM before initiating treatment as standard of care. Earlier treatment may benefit pts with S...